UK government plans to increase the price the NHS pays for drugs will face a legal challenge from a patient campaign group. The changes, announced in December 2025, formed a key part of a trade deal aimed at avoiding tariffs being imposed by the US president, Donald Trump.1 These new regulations would allow ministers to increase the cost threshold that the National Institute for Health and Care Excellence (NICE) uses to determine which drugs are made routinely available in the health service from a range of £20 000-£30 000 per quality adjusted life year to £25 000-£35 000. The change is expected to cost the NHS billions, which critics say could be better spent improving services. But these plans are now being challenged by Just Treatment, a patient led campaign group working alongside Global Justice Now, a social justice organisation. The two groups have written to …